These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25730316)

  • 1. Potential small guide RNAs for tRNase ZL from human plasma, peripheral blood mononuclear cells, and cultured cell lines.
    Ninomiya S; Kawano M; Abe T; Ishikawa T; Takahashi M; Tamura M; Takahashi Y; Nashimoto M
    PLoS One; 2015; 10(3):e0118631. PubMed ID: 25730316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL.
    Habu Y; Miyano-Kurosaki N; Kitano M; Endo Y; Yukita M; Ohira S; Takaku H; Nashimoto M; Takaku H
    Nucleic Acids Res; 2005; 33(1):235-43. PubMed ID: 15647506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRUE Gene Silencing.
    Nashimoto M
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential physiological roles of the 31/32-nucleotide Y4-RNA fragment in human plasma.
    Ninomiya S; Ishikawa T; Takahashi M; Seki M; Nashimoto M
    Noncoding RNA Res; 2019 Dec; 4(4):135-140. PubMed ID: 32072081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The T loop structure is dispensable for substrate recognition by tRNase ZL.
    Shibata HS; Takaku H; Takagi M; Nashimoto M
    J Biol Chem; 2005 Jun; 280(23):22326-34. PubMed ID: 15824113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of specific miRNAs by naked 14-nt sgRNAs.
    Takahashi M; Elbarbary RA; Abe M; Sato M; Yoshida T; Yamada Y; Tamura M; Nashimoto M
    PLoS One; 2012; 7(6):e38496. PubMed ID: 22675569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of gene expression by human cytosolic tRNase Z(L) through 5'-half-tRNA.
    Elbarbary RA; Takaku H; Uchiumi N; Tamiya H; Abe M; Takahashi M; Nishida H; Nashimoto M
    PLoS One; 2009 Jun; 4(6):e5908. PubMed ID: 19526060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity.
    Takaku H; Minagawa A; Takagi M; Nashimoto M
    Nucleic Acids Res; 2004; 32(15):4429-38. PubMed ID: 15317868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cytosolic tRNase ZL can downregulate gene expression through miRNA.
    Elbarbary RA; Takaku H; Uchiumi N; Tamiya H; Abe M; Nishida H; Nashimoto M
    FEBS Lett; 2009 Oct; 583(19):3241-6. PubMed ID: 19751732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of double heptamer-type sgRNA as a potential therapeutic agent against multiple myeloma.
    Ishikawa T; Haino A; Ichiyanagi T; Seki M; Nashimoto M
    Blood Cells Mol Dis; 2019 Nov; 79():102341. PubMed ID: 31226499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the utility of heptamer-type sgRNA for TRUE gene silencing.
    Sano T; Takahashi M; Nozaki T; Takahashi Y; Tamura M; Nashimoto M
    Biochem Biophys Res Commun; 2011 Dec; 416(3-4):427-32. PubMed ID: 22142845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents.
    Haino A; Ishikawa T; Seki M; Nashimoto M
    J Vis Exp; 2016 Jun; (112):. PubMed ID: 27285342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene silencing by the tRNA maturase tRNase ZL under the direction of small-guide RNA.
    Nakashima A; Takaku H; Shibata HS; Negishi Y; Takagi M; Tamura M; Nashimoto M
    Gene Ther; 2007 Jan; 14(1):78-85. PubMed ID: 16885998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel 4-base-recognizing RNA cutter that can remove the single 3' terminal nucleotides from RNA molecules.
    Takaku H; Minagawa A; Takagi M; Nashimoto M
    Nucleic Acids Res; 2004; 32(11):e91. PubMed ID: 15247324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular mRNA cleavage by 3' tRNase under the direction of 2'-O-methyl RNA heptamers.
    Tamura M; Nashimoto C; Miyake N; Daikuhara Y; Ochi K; Nashimoto M
    Nucleic Acids Res; 2003 Aug; 31(15):4354-60. PubMed ID: 12888494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CRISPR/Cas single guide RNAs using small tRNA promoters.
    Mefferd AL; Kornepati AV; Bogerd HP; Kennedy EM; Cullen BR
    RNA; 2015 Sep; 21(9):1683-9. PubMed ID: 26187160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific cleavage of target RNAs from HIV-1 with 5' half tRNA by mammalian tRNA 3' processing endoribonuclease.
    Nashimoto M
    RNA; 1996 Jun; 2(6):523-4. PubMed ID: 8718682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of an intracellular vesicular transport process in naked-sgRNA-mediated TRUE gene silencing.
    Tamura M; Kawano M; Sato M; Nashimoto M
    Mol Med Rep; 2015 Oct; 12(4):6365-9. PubMed ID: 26238202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing.
    Iizuka S; Oridate N; Nashimoto M; Fukuda S; Tamura M
    PLoS One; 2014; 9(12):e114121. PubMed ID: 25437003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of a heptamer-type sgRNA library for potential therapeutic agents against hematological malignancies.
    Takahashi M; Elbarbary RA; Watanabe N; Goto A; Kamiya D; Watabe Y; Uchiyama T; Narita M; Takahashi M; Takahashi Y; Ishihara N; Miyazawa T; Yoshida T; Kawano M; Tamura M; Nashimoto M
    Leuk Res; 2014 Jul; 38(7):808-15. PubMed ID: 24768135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.